Doseology Announces Results of Its Annual General Meeting
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Doseology Sciences (DOSEF) reported that shareholders approved all matters at the company's annual general meeting held on November 18, 2026. Shareholders voted 2,824,597 common shares, representing 34.93% of the 8,086,889 common shares issued and outstanding as of the meeting record date.
Shareholders elected Kareem Baalbaki, Jeremy Wright and Scott Reeves as directors and reappointed Dale Matheson Carr-Hilton Labonte as auditor. They also approved the omnibus equity incentive compensation plan in accordance with Canadian Securities Exchange requirements.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Kelowna, British Columbia--(Newsfile Corp. - November 18, 2026) - Doseology Sciences Inc. (CSE: MOOD) (OTCQB: DOSEF) (FSE: VU70) ("Doseology" or the "Company") is pleased to report that all matters were approved at the Company's annual general meeting of shareholders (the "Meeting") held on November 18, 2026. A total of 2,824,597 common shares were voted, representing
At the Meeting, the Company's shareholders elected Kareem Baalbaki, Jeremy Wright and Scott Reeves as directors of the Company, and approved: (i) the re-appointment of the Company's auditor, Dale Matheson Carr-Hilton Labonte LLP, Chartered Professional Accountants, and (ii) the Company's omnibus equity incentive compensation plan in accordance with the requirements of the Canadian Securities Exchange.
About Doseology Sciences Inc. (CSE: MOOD) (OTCQB: DOSEF) (FSE: VU70)
Doseology Sciences Inc. specializes in pouch-based oral stimulant and cognitive support products. The rapidly expanding oral stimulant pouch sector is gaining momentum as consumers seek modern, discreet alternatives to traditional delivery formats. Unlike combustible tobacco or vape products, oral stimulant pouches are smokeless and vapor-free, providing an alternative delivery method without inhalation.
From a market perspective, the oral pouch category is experiencing strong global growth as consumers increasingly prioritize convenience, portability, and format innovation. The pouch sector represents one of the most dynamic and high-growth areas in modern functional consumer products.
For more information visit: www.doseology.com
On behalf of the Board of Directors,
Kareem Baalbaki, Interim CEO
Doseology Sciences Inc.
Investor & Media Contact:
Email: hello@doseology.com
Phone: 825.800.0115
No securities regulatory authority has either approved or disapproved of the contents of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/324647